Effects of Graves' ophthalmopathy on quality of life

被引:60
作者
Wiersinga, WM
Prummel, MF
Terwee, CB
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Ctr Med, Res Inst Extramural Med, Amsterdam, Netherlands
关键词
Graves' ophthalmopathy; quality of life; GO-QOL;
D O I
10.1007/BF03345275
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
General health-related quality of life is markedly impaired in patients with Graves' ophthalmopathy (GO), and even worse than in patients with other chronic conditions like diabetes, emphysema or heart failure. A disease-specific quality-of-life questionnaire for GO has been developed, the so-called GO-QOL, consisting of two subscales: one for visual functioning (8 questions referring to limitations due to decreased visual acuity and/or diplopia) and one for appearance (8 questions referring to limitations in psychosocial functioning due to changes in appearance). The GO-QOL was found to be a valid and reliable instrument. A minimal clinically important difference (MCID) in the GO-QOL score was derived from data obtained before and after specific eye treatments. Based on the patient's opinions, changes of greater than or equal to 6 points (minor surgery) or greater than or equal to 10 points (surgical decompression, immunosuppression) are recommended as MCID. It is concluded that the GO-QOL is an useful instrument for measuring changes over time in visual functioning and appearance of GO patients. The GO-QOL is available in six languages, and can be used as a separate outcome measure in clinical studies. (C) 2004, Editrice Kurtis.
引用
收藏
页码:259 / 264
页数:6
相关论文
共 25 条
[1]   Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations [J].
Aaronson, NK ;
Muller, M ;
Cohen, PDA ;
Essink-Bot, ML ;
Fekkes, M ;
Sanderman, R ;
Sprangers, MAG ;
Velde, AT ;
Verrips, E .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1055-1068
[2]   Long-term follow-up of Graves ophthalmopathy in an incidence cohort [J].
Bartley, GB ;
Fatourechi, V ;
Kadrmas, EF ;
Jacobsen, SJ ;
Ilstrup, DM ;
Garrity, JA ;
Gorman, CA .
OPHTHALMOLOGY, 1996, 103 (06) :958-962
[3]  
CAMPBELL A, 1976, QUALITY AM LIFE
[4]  
FATOURECHI V, 1994, OPHTHALMOLOGY, V101, P938
[5]   Should quality-of-life needs influence resource allocation? [J].
Fayers, P ;
Bjordal, K .
LANCET, 2001, 357 (9261) :978-978
[6]   Quality of life in patients with Graves' ophthalmopathy is markedly decreased: Measurement by the medical outcomes study instrument [J].
Gerding, MN ;
Terwee, CB ;
Dekker, FW ;
Koornneef, L ;
Prummel, MF ;
Wiersinga, WM .
THYROID, 1997, 7 (06) :885-889
[7]   Users' guides to the medical literature .12. How to use articles about health-related quality of life [J].
Guyatt, GH ;
Naylor, CD ;
Juniper, E ;
Heyland, DK ;
Jaeschke, R ;
Cook, DJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (15) :1232-1237
[8]   MEASUREMENT OF HEALTH-STATUS - ASCERTAINING THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE [J].
JAESCHKE, R ;
SINGER, J ;
GUYATT, GH .
CONTROLLED CLINICAL TRIALS, 1989, 10 (04) :407-415
[9]   Psychosocial factors in subjects with thyroid-associated ophthalmopathy [J].
Kahaly, GJ ;
Hardt, J ;
Petrak, F ;
Egle, UT .
THYROID, 2002, 12 (03) :237-239
[10]  
KAHN JA, 1995, OPHTHAL PLAST RECONS, V11, P109